Literature DB >> 21975859

Which eligible breast conservation patients choose mastectomy in the setting of newly diagnosed breast cancer?

Cameron D Adkisson1, Sanjay P Bagaria, Alexander S Parker, Jillian M Bray, Tammeza Gibson, Colleen S Thomas, Michael G Heckman, Sarah A McLaughlin.   

Abstract

PURPOSE: Breast conserving therapy (BCT) and mastectomy offer equivalent survival for women with newly diagnosed breast cancer (BrCa). Despite this, many women eligible for BCT elect mastectomy. Herein, we identify factors associated with choosing ipsilateral mastectomy instead of BCT when mastectomy is not required.
METHODS: Between July 2007 and June 2010, 520 women with BrCa were treated by a single surgeon who prospectively documented patient eligibility for BCT. For patients who did not require mastectomy (n=392), we evaluated associations between treatment choice and potential predictors using odds ratios (ORs) obtained from multivariable logistic regression models. P values≤0.0029 were significant after correction for multiple testing.
RESULTS: Of 392 women eligible for BCT, 106 (27%) chose mastectomy and 286 (73%) chose BCT. Multivariate analysis found an increased likelihood of electing mastectomy over BCT for patients with no comorbidities (OR 5.4; P<0.001) and those with previous mastectomy (OR 23.2; P<0.001). MRI and biopsy findings were associated with treatment choice because patients who had a second-site biopsy positive for cancer in the same quadrant as the index tumor were more likely to elect mastectomy compared with patients with no additional MRI abnormalities (OR 4.3; P=0.0027). No association existed on multivariate analysis between choice of mastectomy and patient age, family history, or tumor stage.
CONCLUSIONS: One in four eligible BCT patients chooses mastectomy. Factors independently associated with choosing mastectomy over BCT include findings of second-site biopsy, previous mastectomy, and absence of comorbidities but not primary tumor characteristics. Further study into a patient’s choice for mastectomy is warranted.

Entities:  

Mesh:

Year:  2012        PMID: 21975859     DOI: 10.1245/s10434-011-2080-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

1.  Borderline atypical ductal hyperplasia/low-grade ductal carcinoma in situ on breast needle core biopsy should be managed conservatively.

Authors:  Christopher J Vandenbussche; Nagi Khouri; Eman Sbaity; Theodore N Tsangaris; Russell Vang; Armanda Tatsas; Ashley Cimino-Mathews; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2013-06       Impact factor: 6.394

2.  Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.

Authors:  Mehra Golshan; Sibylle Loibl; Stephanie M Wong; Jens Bodo Houber; Joyce O'Shaughnessy; Hope S Rugo; Norman Wolmark; Mark D McKee; David Maag; Danielle M Sullivan; Otto Metzger-Filho; Gunter Von Minckwitz; Charles E Geyer; William M Sikov; Michael Untch
Journal:  JAMA Surg       Date:  2020-03-18       Impact factor: 14.766

3.  Realization of a biomechanical model-assisted image guidance system for breast cancer surgery using supine MRI.

Authors:  Rebekah H Conley; Ingrid M Meszoely; Jared A Weis; Thomas S Pheiffer; Lori R Arlinghaus; Thomas E Yankeelov; Michael I Miga
Journal:  Int J Comput Assist Radiol Surg       Date:  2015-06-20       Impact factor: 2.924

4.  Effect of breast-conserving surgery plus radiotherapy versus mastectomy on breast cancer-specific survival for early-stage contralateral breast cancer.

Authors:  Chao Qian; Yan Liang; Min Yang; Sheng-Nan Bao; Jian-Ling Bai; Yong-Mei Yin; Hao Yu
Journal:  Gland Surg       Date:  2021-10

5.  Factors associated with patients in the Scottish Highlands who chose mastectomy when suitable for breast conservation.

Authors:  Rosalyn Shearer; Majid Rashid; Gill Hubbard; Nick Abbott; Ian Daltrey; Russell Mullen
Journal:  Gland Surg       Date:  2016-08

6.  Considerations arising from requests from patients for a bilateral mastectomy who are eligible for breast-conserving surgery: Factors weighing for and against performing the operation.

Authors:  Alessandro Fancellu
Journal:  Oncol Lett       Date:  2016-05-30       Impact factor: 2.967

7.  Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).

Authors:  Mehra Golshan; Constance T Cirrincione; William M Sikov; Donald A Berry; Sara Jasinski; Tracey F Weisberg; George Somlo; Clifford Hudis; Eric Winer; David W Ollila
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

8.  Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.

Authors:  Li Cao; Guang-yu Yao; Min-feng Liu; Lu-jia Chen; Xiao-lei Hu; Chang-sheng Ye
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

9.  Breast conservation surgery versus total mastectomy among women with localized breast cancer in Soweto, South Africa.

Authors:  Herbert Cubasch; Maureen Joffe; Paul Ruff; Donald Dietz; Evan Rosenbaum; Nivashni Murugan; Ming Tsai Chih; Oluwatosin Ayeni; Caroline Dickens; Katherine Crew; Judith S Jacobson; Alfred Neugut
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

Review 10.  Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials.

Authors:  Jinli Wei; Yulin Luo; Deyuan Fu
Journal:  Onco Targets Ther       Date:  2018-12-12       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.